Author(s):
Sakshi Tandel, Kantilal Narkhede, Anuradha Prajapati, Sachin Narkhede, Shailesh Luhar, Hetvi Pastagia
Email(s):
sakshitandel32@gmail.com
DOI:
10.52711/2231-5691.2026.00043 
Address:
Sakshi Tandel¹*, Kantilal Narkhede, Anuradha Prajapati, Sachin Narkhede, Shailesh Luhar, Hetvi Pastagia
Smt. B.N.B Swaminarayan Pharmacy College, Salvav-Vapi, Gujarat, 396191, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2026
ABSTRACT:
Cancer remains a massive global challenge, constantly pushing us to find smarter treatments. Among various nanocarriers, dendrimers have captured significant attention due to their tiny size, unique branched shape, and adaptable surfaces, making them excellent for drug loading and adding special functions. However, using pure dendrimers in patients has proven tricky because they can be a bit toxic, aren't always super compatible with our bodies, and get cleared out quickly. To overcome these issues, scientists have cleverly developed dendrimer-based hybrid systems, combining dendrimers with other nanomaterials like lipids, polymers, metals, and carbon structures. This "best of both worlds" approach is a game-changer, as these hybrids leverage the strengths of each component to boost drug delivery efficiency, improve targeting accuracy, and enhance their power against aggressive cancers like glioblastoma and metastatic tumors. Recent breakthroughs include dendrimer-lipid constructs for better biocompatibility, polymer-dendrimer hybrids for controlled release, and metal-dendrimer systems that offer both therapeutic (like photothermal therapy!) and diagnostic capabilities. While challenges like complex synthesis, safety assessment, and regulatory hurdles persist, innovations such as smart, stimuli-responsive designs and AI-driven formulation approaches are paving the way for these promising candidates to achieve clinical success, offering greater adaptability and precision compared to conventional nanocarriers for future combination therapies and truly personalized cancer treatment.
Cite this article:
Sakshi Tandel, Kantilal Narkhede, Anuradha Prajapati, Sachin Narkhede, Shailesh Luhar, Hetvi Pastagia. Dendrimer Hybrids in Synergistic Cancer Therapy: A New Frontier in Nanomedicine. Asian Journal of Pharmaceutical Research. 2026; 16(3):289-4. doi: 10.52711/2231-5691.2026.00043
Cite(Electronic):
Sakshi Tandel, Kantilal Narkhede, Anuradha Prajapati, Sachin Narkhede, Shailesh Luhar, Hetvi Pastagia. Dendrimer Hybrids in Synergistic Cancer Therapy: A New Frontier in Nanomedicine. Asian Journal of Pharmaceutical Research. 2026; 16(3):289-4. doi: 10.52711/2231-5691.2026.00043 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2026-16-3-11
9. REFERENCE:
1. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev. 2005; 57(15): 2106–29.
2. Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today. 2005; 10(1): 35–43.
3. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci. 2014; 39(2): 268–307.
4. Chauhan AS. Dendrimers for drug delivery. Molecules. 2018; 23(4): 938.
5. Kannan RM, Nance E, Kannan S, Tomalia DA. Emerging concepts in dendrimer-based nanomedicine. J Intern Med. 2014; 276(6): 579–617.
6. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: Let’s meet the challenge. Int J Pharm. 2010; 394(1–2): 122–42.
7. Bai S, Thomas C, Rawat A. Dendrimer–lipid nanohybrids for anticancer drug delivery. Nanomedicine. 2019; 20:101986.
8. Huang D, Zhou H, Liu Y, Xu P. Dendrimer-based nanohybrids for cancer theranostics. Mater Today Bio. 2021; 10: 100109.
9. Tripathy S, Das MK, Das S. Dendrimer-based hybrid nanocarriers: Recent advances in cancer therapy. Artif Cells Nanomed Biotechnol. 2020; 48(1): 118.
10. Parveen S, Sahoo SK. Dendrimer–polymer hybrid nanostructures for cancer therapy. Expert Opin Drug Deliv. 2011; 8(7): 839–56.
11. Kesharwani P, Gupta U. Dendrimer–metal nanoparticle conjugates for cancer therapy. J Control Release. 2021; 330: 620–38.
12. Wang J, Liu X, Jin X. Dendrimer–carbon nanostructure hybrids in drug delivery and imaging. J Nanobiotechnology. 2020;18(1):130.
13. Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM. Nanoparticle-based delivery of cancer drugs. Annu Rev Biomed Eng. 2012; 14: 185–210.
14. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: An update review. Curr Drug Deliv. 2007; 4(4): 297–305.
15. Tyagi N, Dhanjal JK, Mehta M. Dendrimer-based therapeutic systems. Int J Pharm. 2022; 617: 121564.
16. Boyd BJ, Porter CJH. VivaGel®: Clinical translation of dendrimer-based antivirals. Expert Opin Drug Deliv. 2019; 16(5): 493–503.
17. Mukherjee S. AI-assisted nanomedicine formulation: Personalized therapy. Comput Struct Biotechnol J. 2023; 21: 530–42.
18. Singh D, Singh M. Tumor microenvironment-responsive dendrimer systems. Front Pharmacol. 2022; 13: 856790.
19. Munro, N., Srinageshwar, B., Shalabi, F., Florendo, M., Otero, P., Thompson, C. A novel approach to label bone marrow-derived mesenchymal stem cells with mixed-surface PAMAM dendrimers. Stem Cell Research and Therapy. 2019; 10(1): 71.
20. Cleveland Clinic. Glioblastoma (GBM): What It Is, Symptoms & Prognosis. Cleveland Clinic Health Library. Last reviewed: April 23, 2025. Available from: https://my.clevelandclinic.org/health/diseases/17032-glioblastoma.